NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
NITRO-DUR (nitroglycerin) by Pfizer is clinical pharmacology the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. First approved in 1985.
Drug data last refreshed 19h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NITRO-DUR is a transdermal extended-release nitroglycerin patch approved in 1985 for coronary artery disease and heart failure. It works by relaxing vascular smooth muscle, dilating peripheral arteries and veins to reduce cardiac preload and afterload while improving coronary blood flow. The drug is indicated across multiple cardiovascular conditions including hypertension, aortic stenosis, and cerebral vasospasm.
$3MPart D
LOE ApproachingDeclining
With LOE approaching and minimal Part D spending, NITRO-DUR is a legacy product with limited team expansion opportunity and focus on transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…
Worked on NITRO-DUR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.